<DOC>
	<DOC>NCT00699231</DOC>
	<brief_summary>This trial is designed to evaluate the immunogenicity, reactogenicity and safety of an MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in haemodialysis patients with or without previous vaccination against hepatitis B</brief_summary>
	<brief_title>Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients</brief_title>
	<detailed_description>At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Dialysis patients A medical examination including physical examination and medical history as well as serological screening established acceptability for enrollment into the study. Age: from 18 years onwards Seronegative for anti hepatitis antibodies History of persistent hepatic, cardiac or respiratory disease Any acute disease at the moment of entry into the study Chronic alcohol consumption Hepatomegaly, right upper quadrant pain or tenderness Any treatment with coticosteroids or immunomodulating drugs Known hypersensitivity to any component of the vaccine Simultaneous participation in any other clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>